Aug 2021 Articles

Articles
2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee
Salim S Virani, Pamela B Morris, Anandita Agarwala, et al.
Journal:
J Am Coll Cardiol 2021 Aug 31;78(9):960-993

First published: August 31, 2021 DOI: 10.1016/j.jacc.2021.06.011
View
- Share
Articles
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies. With the special contribution of the European Association of Preventive Cardiology (EAPC)
Frank L J Visseren, François Mach, Yvo M Smulders, et al.
Journal:
European Heart Journal August 2021; ehab484.

First published: August 30, 2021 DOI: 10.1093/eurheartj/ehab484
View
- Share
Articles
Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL
Marston NA, Giugliano RP, Park JG, et al.
Journal:
Circulation

First published: August 27, 2021 DOI: 10.1161/CIRCULATIONAHA.121.056536
View
- Share
Articles
Target Populations and Treatment Cost for Bempedoic Acid and PCSK9 Inhibitors: A Simulation Study in a Contemporary CAD Cohort
Christopher Blaum, Fabian J Brunner, Alina Goßling, et al
Journal:
Clin Ther. 2021 Aug 24;S0149-2918(21)00263-0

First published: August 27, 2021 DOI: 10.1016/j.clinthera.2021.07.019
View
- Share
Articles
Association of Statin Treatment With Progression of Coronary Atherosclerotic Plaque Composition
Alexander R van Rosendael, Inge J van den Hoogen, Umberto Gianni, et al.
Journal:
JAMA Cardiol 2021 Aug 18

First published: August 18, 2021 DOI: 10.1001/jamacardio.2021.3055
View
- Share
Articles
Familial hypercholesterolemia and COVID-19: A menacing but treatable vasculopathic condition
Vuorio A, Strandberg TE, Raal F, et al.
Journal:
Atheroscler Plus

First published: August 8, 2021 DOI: 10.1016/j.athplu.2021.08.001
View
- Share
Articles
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
Schwartz GG, Szarek M, Bittner VA, et al.
Journal:
J Am Coll Cardiol 2021 Aug 3;78(5):421-433

First published: August 3, 2021 DOI: 10.1016/j.jacc.2021.04.102
View
- Share

Aug 2021 Articles

Articles

2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee

Salim S Virani, Pamela B Morris, Anandita Agarwala, et al.

Articles

Frank L J Visseren, François Mach, Yvo M Smulders, et al.

Articles

Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL

Marston NA, Giugliano RP, Park JG, et al.

Articles

Target Populations and Treatment Cost for Bempedoic Acid and PCSK9 Inhibitors: A Simulation Study in a Contemporary CAD Cohort

Christopher Blaum, Fabian J Brunner, Alina Goßling, et al

Articles

Association of Statin Treatment With Progression of Coronary Atherosclerotic Plaque Composition

Alexander R van Rosendael, Inge J van den Hoogen, Umberto Gianni, et al.

Articles

Familial hypercholesterolemia and COVID-19: A menacing but treatable vasculopathic condition

Vuorio A, Strandberg TE, Raal F, et al.

Articles

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Schwartz GG, Szarek M, Bittner VA, et al.

Articles

2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee

Salim S Virani, Pamela B Morris, Anandita Agarwala, et al.

Share

Articles

Frank L J Visseren, François Mach, Yvo M Smulders, et al.

Share

Articles

Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL

Marston NA, Giugliano RP, Park JG, et al.

Share

Articles

Target Populations and Treatment Cost for Bempedoic Acid and PCSK9 Inhibitors: A Simulation Study in a Contemporary CAD Cohort

Christopher Blaum, Fabian J Brunner, Alina Goßling, et al

Share

Articles

Association of Statin Treatment With Progression of Coronary Atherosclerotic Plaque Composition

Alexander R van Rosendael, Inge J van den Hoogen, Umberto Gianni, et al.

Share

Articles

Familial hypercholesterolemia and COVID-19: A menacing but treatable vasculopathic condition

Vuorio A, Strandberg TE, Raal F, et al.

Share

Articles

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Schwartz GG, Szarek M, Bittner VA, et al.

Share